Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cholic Acid

FDA-approved product (capsule, oral), marketed as Cholbam.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cholic Acid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormality of the gastrointestinal tract
  • Inborn errors of metabolism
  • Liver disease
  • Peroxisomal disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bile acids and derivatives
FDA pharmacologic class
Bile Acid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cholic Acid in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cholic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

    NCT07378761 · start 2026-06-25

    Registered record
    Registry ID
    NCT07378761
    Conditions
    Immune-Mediated Cholestasis
    Interventions
    UDCA (Ursodeoxycholic acid); Corticosteroids (Reference Treatment)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-25
    Completion
    2028-12
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune-Mediated Cholestasis
    InterventionUDCA (Ursodeoxycholic acid); Corticosteroids (Reference Treatment)
    PhasePhase 2
    Registry statusRecruiting

  • Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

    NCT07672860 · start 2026-06-01

    Registered record
    Registry ID
    NCT07672860
    Conditions
    Kidney Cancer
    Interventions
    UDCA (Ursodeoxycholic acid); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-01
    Completion
    2027-12
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    InterventionUDCA (Ursodeoxycholic acid); Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

    NCT06884748 · start 2026-05-01

    Registered record
    Registry ID
    NCT06884748
    Conditions
    Clostridioides Difficile Infection
    Interventions
    Ursodiol 500 MG
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2028-05-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClostridioides Difficile Infection
    InterventionUrsodiol 500 MG
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • UDCA to Prevent Post-TIPS Hepatic Encephalopathy

    NCT07273734 · start 2026-01-01

    Registered record
    Registry ID
    NCT07273734
    Conditions
    Hepatic Encephalopathy (HE); TIPS
    Interventions
    Ursodeoxycholic Acid (UDCA); Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-01-01
    Completion
    2027-12-31
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy (HE); TIPS
    InterventionUrsodeoxycholic Acid (UDCA); Lactulose
    PhaseNot applicable
    Registry statusNot yet recruiting

  • HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

    NCT06899152 · start 2025-07-16

    Registered record
    Registry ID
    NCT06899152
    Conditions
    Liver Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Cholangiocarcinoma; Liver Metastases
    Interventions
    HepQuant DuO; Multiparametric MRI Scans
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-07-16
    Completion
    2031-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Cholangiocarcinoma +1 more
    InterventionHepQuant DuO; Multiparametric MRI Scans
    PhaseNot applicable
    Registry statusRecruiting

  • Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

    NCT07068191 · start 2025-06-19

    Registered record
    Registry ID
    NCT07068191
    Conditions
    Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Hepatomegaly; Nonalcoholic Fatty Liver (NAFL); Nonalcoholic Fatty Liver Disease (NAFLD); Fatty Liver; Fatty Liver, Alcoholic; Fatty Liver, Nonalcoholic; Fatty Liver Disease
    Interventions
    Dietary supplement "Gepaktiv"; UDCA (Ursodeoxycholic acid); Ademetionine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-06-19
    Completion
    2025-08
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Hepatomegaly; Nonalcoholic Fatty Liver (NAFL); Nonalcoholic Fatty Liver Disease (NAFLD) +4 more
    InterventionDietary supplement "Gepaktiv"; UDCA (Ursodeoxycholic acid); Ademetionine
    PhaseNot applicable
    Registry statusRecruiting

  • A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

    NCT06783621 · start 2025-01-16

    Registered record
    Registry ID
    NCT06783621
    Conditions
    Facial Contouring
    Interventions
    OnabotulinumtoxinA; JUVÉDERM; CoolSculpting Elite System; SkinMedica Products; KYBELLA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-01-16
    Completion
    2026-03-20
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFacial Contouring
    InterventionOnabotulinumtoxinA; JUVÉDERM; CoolSculpting Elite System; SkinMedica Products +1 more
    PhasePhase 4
    Registry statusCompleted

  • Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance

    NCT06684106 · start 2024-11-25

    Registered record
    Registry ID
    NCT06684106
    Conditions
    Hyperlipidemia; Ursodeoxycholic Acid; Statin Therapy; Glucose Intolerance
    Interventions
    Ursodeoxycholic acid (UDCA) 500 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-11-25
    Completion
    2027-06-01
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia; Ursodeoxycholic Acid; Statin Therapy; Glucose Intolerance
    InterventionUrsodeoxycholic acid (UDCA) 500 mg; Placebo
    PhaseNot applicable
    Registry statusRecruiting

  • A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

    NCT06591455 · start 2024-09-14

    Registered record
    Registry ID
    NCT06591455
    Conditions
    Primary Biliary Cholangitis (PBC)
    Interventions
    Fenofibrate; UDCA (Ursodeoxycholic acid)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-09-14
    Completion
    2025-08-18
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cholangitis (PBC)
    InterventionFenofibrate; UDCA (Ursodeoxycholic acid)
    PhaseEarly phase 1
    Registry statusCompleted

  • Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

    NCT06132165 · start 2024-03-01

    Registered record
    Registry ID
    NCT06132165
    Conditions
    Neurofibromatosis 1
    Interventions
    Deoxycholic Acid; Polidocanol; 1064nm Nd:YAG laser; 755nm Alexandrite Laser
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-03-01
    Completion
    2025-07-31
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurofibromatosis 1
    InterventionDeoxycholic Acid; Polidocanol; 1064nm Nd:YAG laser; 755nm Alexandrite Laser
    PhasePhase 1
    Registry statusCompleted

  • Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus

    NCT05902468 · start 2023-06-28

    Registered record
    Registry ID
    NCT05902468
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Ursodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-06-28
    Completion
    2024-11-28
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionUrsodeoxycholic acid
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases

    NCT04531878 · start 2023-02-08

    Registered record
    Registry ID
    NCT04531878
    Conditions
    Hereditary Diseases; Cholestasis, Intrahepatic
    Interventions
    4-Phenylbutyrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2023-02-08
    Completion
    2023-02-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Diseases; Cholestasis, Intrahepatic
    Intervention4-Phenylbutyrate
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

    NCT05849558 · start 2022-02-22

    Registered record
    Registry ID
    NCT05849558
    Conditions
    Chronic Liver Disease
    Interventions
    Ursoplus; UDCA 250mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-02-22
    Completion
    2023-12-31
    Enrolment
    297

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Liver Disease
    InterventionUrsoplus; UDCA 250mg; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin

    NCT05500937 · start 2021-03-01

    Registered record
    Registry ID
    NCT05500937
    Conditions
    Diabetes Mellitus
    Interventions
    UDCA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-03-01
    Completion
    2024-12-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionUDCA
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II

    NCT04617561 · start 2020-11-01

    Registered record
    Registry ID
    NCT04617561
    Conditions
    Hepatitis, Autoimmune; Primary Biliary Cholangitis
    Interventions
    Ursodeoxycholic acid; Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-11-01
    Completion
    2022-11-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis, Autoimmune; Primary Biliary Cholangitis
    InterventionUrsodeoxycholic acid; Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
    PhasePhase 4
    Registry statusUnknown